Recent work suggests ibrutinib to down-modulate CCR7 expression and function in CLL (e.g. integrin activation and receptor recycling) and by that to restore the balance between CCR7 and S1P1 and to enforce nodal egress of leukemic cells (44, 46). Here, CCR7 is linked to B-cell chronic lymphocytic leukemia.